United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.

Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline

Gilead Sciences

Paycom Software

Pfizer is busy growing income streams to replace its big COVID-related revenue from years past. Paycom is profitably helping companies help themselves with self-service software.

3 Stocks That Can Help You to Get Richer in 2024 and Beyond

Pfizer's weight loss candidate is moving closer to pivotal studies. This product had encouraging results in phase 2 studies.

Beware, Wegovy -- Pfizer Is Working on a Competitor

BioNTech SE

Britain's health regulator said on Wednesday it has authorised Pfizer and BioNTech's updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adults.

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant

Sangamo Therapeutics

Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.

Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study

Pfizer ( PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share, respectively.

Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?

Pfizer is developing danuglipron -- a once-daily weight loss drug. In studies of a twice-daily version, some trial participants lost more than 10% of their body weight.

This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer

Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.

Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial

Pfizer said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment.

Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial

Pfizer Inc. PFE, -0.34% announced positive results Wednesday from a late-stage trial of a gene therapy as a treatment for adults with moderately severe to severe Hemophilia A. The Phase 3 trial called Affine sought to evaluate giroctocogene fitelparvovec as a treatment for the blood-clotting disorder and met its primary and secondary endpoints.

Pfizer announces positive results from late-stage trial of Hemophilia A treatment

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with rou.

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline

Roche Holding AG

Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible.

Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche

Pfizer doesn't currently produce any anti-obesity medicines, but it wants to do so. However, its most mature program on that front isn't exactly a sizzler.

Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.

Valneva SE

On Wednesday, Pfizer Inc PFE and Valneva SE VALN announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15.

Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026

Pfizer stock has surged this month on enthusiasm for its efforts in obesity treatment. Is PFE stock now a buy?

Is Pfizer Stock A Buy After Breaking Out On Obesity Treatment Fervor?

Pfizer Inc PFE, one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.

Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio

Alibaba

Disney

EPR Properties

Intel

Lithium Americas Corp

Western Union

The stock market has been on a tear lately, but not all stocks are sharing in the gains. A handful of industries and outlier companies are driving the broader market rally, while many other stocks have been left behind.

7 Hated Stocks Set to Make a Major Comeback This Year

AT&T

Dividend stocks have crushed non-payers in the return column over the last 50 years. No two dividend stocks are cut from the same cloth, which means proper vetting is needed to snag high-quality income stocks with outsized yields.

Time to Pounce: 2 Beaten-Down Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought Right Now

New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.1 ,

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Eli Lilly

Merck

Novo Nordisk

Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer

Lee and I have a list of stocks we love to hate, and one of Lee's picks is Pfizer (NYSE: PFE).

Wall St Veteran Names Worst Value Trap in the World

NVIDIA

Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round.

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason

The European Commission did not allow the public enough access to information about COVID-19 vaccine purchase agreements it secured with pharmaceutical companies during the pandemic, the EU general court said Wednesday.

European Commission didn't provide enough information about COVID-19 vaccine deals, EU court says

Cisco Systems

If you're a DIY investor who's just starting out, you may not have enough cash on the sidelines to buy a stock that's going for north of $4,000 per share. Booking Holdings (NASDAQ: BKNG ), for example, is one of those incredibly high-priced stocks that's way out of reach for smaller investors who don't have four figures of new cash to put on a single stock.

News for Pfizer Stock (PFE)